Plasmids expressing heavy and kappa chains, which when co-transfected into mammalian cells (such as 293F) will produce secreted antibody mBG86 that recognizes SARS-CoV-2 nucleocapsid antigen.
A panel of mouse monoclonal antibodies targeting the SARS-CoV-2 N protein were generated and characterized. Truncated recombinant N protein was expressed and purified, used the recombinant antigen to immunize mice and generated a panel of hybridomas, and tested the resulting clones for activity in western blots, ELISAs, and immunofluorescence assays with SARS-CoV-2 infected cells. Cross-reactivity of the antibodies against SARS-CoV, MERS-CoV, HuCoV-NL63, HuCoV-HKU1, HuCoV-OC43and HuCoV-229E N protein was tested.
From the laboratory of Brian J. Geiss, PhD, Colorado State University.
|Gene/insert name:||pBG718, Anti-[mBG86] Heavy Chain Expression Plasmid|
|Grow in E. coli at 37 C:||Yes|
|Cloning Site 5':||SacI|
|Cloning Site 3':||NotI|
|Insert Size:||1461 bp (Heavy) 723 bp (Kappa)|
|Vector Backbone and Size:||pCMV (3952 bp)|
|High or low copy:||High|
1. James S. Terry, Loran BR. Anderson, Michael S. Scherman, Carley E. McAlister, Rushika Perera, Tony Schountz, Brian J. Geiss. Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody. Virology. 2020 Sep 3:2020;09.03.280370. View Article
If you publish research with this product, please let us know so we can cite your paper.